Skip to main content
Top
Published in: BMC Nephrology 1/2013

Open Access 01-12-2013 | Case report

Long term follow up of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) on hemodialysis for 19 years: a case report

Authors: Koki Mise, Yoshifumi Ubara, Masanori Matsumoto, Keiichi Sumida, Rikako Hiramatsu, Eiko Hasegawa, Masayuki Yamanouchi, Noriko Hayami, Tatsuya Suwabe, Junichi Hoshino, Naoki Sawa, Kenichi Ohashi, Koichi Kokame, Toshiyuki Miyata, Yoshihiro Fujimura, Kenmei Takaichi

Published in: BMC Nephrology | Issue 1/2013

Login to get access

Abstract

Background

Thrombotic thrombocytopenic purpura (TTP) is frequently associated with renal abnormalities, but there have been few reports about renal abnormalities in patients with hereditary TTP. In particular, little is known about the long-term prognosis of patients with childhood-onset congenital TTP.

Case presentation

We report a Japanese patient with congenital TTP (Upshaw–Schulman syndrome) who was followed for 19 years after initiation of hemodialysis when he was 22 years old. At the age of 6 years, the first episode of purpura, thrombocytopenia, and proteinuria occurred without any precipitating cause. He underwent living-related donor kidney transplantation from his mother, but the graft failed after 5 months due to recurrence of TTP. Even after resection of the transplanted kidney and resumption of regular hemodialysis, TTP became refractory to infusion of fresh frozen plasma (FFP). Therefore, splenectomy was performed and his disease remained in remission for 10 years. However, TTP recurred at the age of 39 years. Plasma activity of ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type I domain 13) was less than 3%, while ADAMTS13 inhibitor was not detected (< 0.5 Bethesda units/mL). The patient died suddenly after hemodialysis at the age of 41 years. Subsequent genetic analysis of this patient and his parents revealed two different heterozygous mutations of ADAMTS13, including a missense mutation in exon 26 (c.3650T>C causing p.I1217T) inherited from his father and a missense mutation in exon 21 (c.2723G>A causing p.C908Y) inherited from his mother. The former mutation has not been detected before in Japan, while the latter mutation is common in Japan. A retrospective review showed that serum C3 levels were consistently low while C4 levels were normal during follow-up, and C3 decreased much further during each episode of TTP.

Conclusion

Congenital TTP was diagnosed from the clinical, biochemical, and genetic findings. Infusion of FFP controlled each thrombotic episode, but the effect was limited and of short duration. Review of the complement profile in this patient suggested that a persistently low serum C3 level might be associated with refractory TTP and a worse renal prognosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bianchi V, Robles R, Alberio L, Furlan M, Lammle B: Von willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002, 100 (2): 710-713. 10.1182/blood-2002-02-0344.CrossRefPubMed Bianchi V, Robles R, Alberio L, Furlan M, Lammle B: Von willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood. 2002, 100 (2): 710-713. 10.1182/blood-2002-02-0344.CrossRefPubMed
2.
go back to reference Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, et al: Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001, 413 (6855): 488-494. 10.1038/35097008.CrossRefPubMed Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, et al: Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001, 413 (6855): 488-494. 10.1038/35097008.CrossRefPubMed
3.
go back to reference Ruggeri ZM: Structure and function of von willebrand factor. Thromb Haemost. 1999, 82 (2): 576-584.PubMed Ruggeri ZM: Structure and function of von willebrand factor. Thromb Haemost. 1999, 82 (2): 576-584.PubMed
4.
go back to reference Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, Ishikawa M, Iwamoto TA, Mori T, Wanaka A, Fukui H, et al: Localization of ADAMTS13 to the stellate cells of human liver. Blood. 2005, 106 (3): 922-924. 10.1182/blood-2005-01-0152.CrossRefPubMed Uemura M, Tatsumi K, Matsumoto M, Fujimoto M, Matsuyama T, Ishikawa M, Iwamoto TA, Mori T, Wanaka A, Fukui H, et al: Localization of ADAMTS13 to the stellate cells of human liver. Blood. 2005, 106 (3): 922-924. 10.1182/blood-2005-01-0152.CrossRefPubMed
5.
go back to reference Zhou W, Inada M, Lee TP, Benten D, Lyubsky S, Bouhassira EE, Gupta S, Tsai HM: ADAMTS13 Is expressed in hepatic stellate cells. Lab Invest. 2005, 85 (6): 780-788. 10.1038/labinvest.3700275.CrossRefPubMedPubMedCentral Zhou W, Inada M, Lee TP, Benten D, Lyubsky S, Bouhassira EE, Gupta S, Tsai HM: ADAMTS13 Is expressed in hepatic stellate cells. Lab Invest. 2005, 85 (6): 780-788. 10.1038/labinvest.3700275.CrossRefPubMedPubMedCentral
6.
go back to reference Manea M, Kristoffersson A, Schneppenheim R, Saleem MA, Mathieson PW, Morgelin M, Bjork P, Holmberg L, Karpman D: Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol. 2007, 138 (5): 651-662. 10.1111/j.1365-2141.2007.06694.x.CrossRefPubMed Manea M, Kristoffersson A, Schneppenheim R, Saleem MA, Mathieson PW, Morgelin M, Bjork P, Holmberg L, Karpman D: Podocytes express ADAMTS13 in normal renal cortex and in patients with thrombotic thrombocytopenic purpura. Br J Haematol. 2007, 138 (5): 651-662. 10.1111/j.1365-2141.2007.06694.x.CrossRefPubMed
8.
go back to reference Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T: FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005, 129 (1): 93-100. 10.1111/j.1365-2141.2005.05420.x.CrossRefPubMed Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T: FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol. 2005, 129 (1): 93-100. 10.1111/j.1365-2141.2005.05420.x.CrossRefPubMed
9.
go back to reference Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, et al: von willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998, 339 (22): 1578-1584. 10.1056/NEJM199811263392202.CrossRefPubMed Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, et al: von willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998, 339 (22): 1578-1584. 10.1056/NEJM199811263392202.CrossRefPubMed
10.
go back to reference Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y: Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion. 2006, 46 (8): 1444-1452. 10.1111/j.1537-2995.2006.00914.x.CrossRefPubMed Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y: Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion. 2006, 46 (8): 1444-1452. 10.1111/j.1537-2995.2006.00914.x.CrossRefPubMed
11.
go back to reference Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, Raskob GE: ADAMTS13 Activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003, 102 (1): 60-68. 10.1182/blood-2003-01-0193.CrossRefPubMed Vesely SK, George JN, Lammle B, Studt JD, Alberio L, El-Harake MA, Raskob GE: ADAMTS13 Activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003, 102 (1): 60-68. 10.1182/blood-2003-01-0193.CrossRefPubMed
12.
go back to reference Raife T, Atkinson B, Montgomery R, Vesely S, Friedman K: Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion. 2004, 44 (2): 146-150. 10.1111/j.1537-2995.2004.00626.x.CrossRefPubMed Raife T, Atkinson B, Montgomery R, Vesely S, Friedman K: Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion. 2004, 44 (2): 146-150. 10.1111/j.1537-2995.2004.00626.x.CrossRefPubMed
13.
go back to reference Zheng XL, Kaufman RM, Goodnough LT, Sadler JE: Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004, 103 (11): 4043-4049. 10.1182/blood-2003-11-4035.CrossRefPubMed Zheng XL, Kaufman RM, Goodnough LT, Sadler JE: Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura. Blood. 2004, 103 (11): 4043-4049. 10.1182/blood-2003-11-4035.CrossRefPubMed
14.
go back to reference Bouw MC, Dors N, van Ommen H, Ramakers-van Woerden NL: Thrombotic thrombocytopenic purpura in childhood. Pediatr Blood Cancer. 2009, 53 (4): 537-542. 10.1002/pbc.22094.CrossRefPubMed Bouw MC, Dors N, van Ommen H, Ramakers-van Woerden NL: Thrombotic thrombocytopenic purpura in childhood. Pediatr Blood Cancer. 2009, 53 (4): 537-542. 10.1002/pbc.22094.CrossRefPubMed
15.
go back to reference Snider CE, Moore JC, Warkentin TE, Finch CN, Hayward CP, Kelton JG: Dissociation between the level of von willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura. Am J Hematol. 2004, 77 (4): 387-390. 10.1002/ajh.20221.CrossRefPubMed Snider CE, Moore JC, Warkentin TE, Finch CN, Hayward CP, Kelton JG: Dissociation between the level of von willebrand factor-cleaving protease activity and disease in a patient with congenital thrombotic thrombocytopenic purpura. Am J Hematol. 2004, 77 (4): 387-390. 10.1002/ajh.20221.CrossRefPubMed
16.
go back to reference Veyradier A, Lavergne JM, Ribba AS, Obert B, Loirat C, Meyer D, Girma JP: Ten candidate ADAMTS13 mutations in six french families with congenital thrombotic thrombocytopenic purpura (upshaw-schulman syndrome). J Thromb Haemost. 2004, 2 (3): 424-429. 10.1111/j.1538-7933.2004.00623.x.CrossRefPubMed Veyradier A, Lavergne JM, Ribba AS, Obert B, Loirat C, Meyer D, Girma JP: Ten candidate ADAMTS13 mutations in six french families with congenital thrombotic thrombocytopenic purpura (upshaw-schulman syndrome). J Thromb Haemost. 2004, 2 (3): 424-429. 10.1111/j.1538-7933.2004.00623.x.CrossRefPubMed
17.
go back to reference Fujimura Y, Matsumoto M, Isonishi A, Yagi H, Kokame K, Soejima K, Murata M, Miyata T: Natural history of upshaw-schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost. 2011, 9 (Suppl 1): 283-301.CrossRefPubMed Fujimura Y, Matsumoto M, Isonishi A, Yagi H, Kokame K, Soejima K, Murata M, Miyata T: Natural history of upshaw-schulman syndrome based on ADAMTS13 gene analysis in Japan. J Thromb Haemost. 2011, 9 (Suppl 1): 283-301.CrossRefPubMed
18.
go back to reference Park HW, Oh D, Kim N, Cho HY, Moon KC, Chae JH, Ahn HS, Choi Y, Cheong HI: Congenital thrombotic thrombocytopenic purpura associated with unilateral moyamoya disease. Pediatr Nephrol. 2008, 23 (9): 1555-1558. 10.1007/s00467-008-0847-5.CrossRefPubMed Park HW, Oh D, Kim N, Cho HY, Moon KC, Chae JH, Ahn HS, Choi Y, Cheong HI: Congenital thrombotic thrombocytopenic purpura associated with unilateral moyamoya disease. Pediatr Nephrol. 2008, 23 (9): 1555-1558. 10.1007/s00467-008-0847-5.CrossRefPubMed
19.
go back to reference Ruiz-Torres MP, Casiraghi F, Galbusera M, Macconi D, Gastoldi S, Todeschini M, Porrati F, Belotti D, Pogliani EM, Noris M, et al: Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost. 2005, 93 (3): 443-452.PubMed Ruiz-Torres MP, Casiraghi F, Galbusera M, Macconi D, Gastoldi S, Todeschini M, Porrati F, Belotti D, Pogliani EM, Noris M, et al: Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost. 2005, 93 (3): 443-452.PubMed
20.
go back to reference Noris M, Bucchioni S, Galbusera M, Donadelli R, Bresin E, Castelletti F, Caprioli J, Brioschi S, Scheiflinger F, Remuzzi G: Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol. 2005, 16 (5): 1177-1183. 10.1681/ASN.2005010086.CrossRefPubMed Noris M, Bucchioni S, Galbusera M, Donadelli R, Bresin E, Castelletti F, Caprioli J, Brioschi S, Scheiflinger F, Remuzzi G: Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol. 2005, 16 (5): 1177-1183. 10.1681/ASN.2005010086.CrossRefPubMed
21.
go back to reference Chapin J, Weksler B, Magro C, Laurence J: Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol. 2012, 157 (6): 772-774. 10.1111/j.1365-2141.2012.09084.x.CrossRefPubMed Chapin J, Weksler B, Magro C, Laurence J: Eculizumab in the treatment of refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol. 2012, 157 (6): 772-774. 10.1111/j.1365-2141.2012.09084.x.CrossRefPubMed
Metadata
Title
Long term follow up of congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) on hemodialysis for 19 years: a case report
Authors
Koki Mise
Yoshifumi Ubara
Masanori Matsumoto
Keiichi Sumida
Rikako Hiramatsu
Eiko Hasegawa
Masayuki Yamanouchi
Noriko Hayami
Tatsuya Suwabe
Junichi Hoshino
Naoki Sawa
Kenichi Ohashi
Koichi Kokame
Toshiyuki Miyata
Yoshihiro Fujimura
Kenmei Takaichi
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2013
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/1471-2369-14-156

Other articles of this Issue 1/2013

BMC Nephrology 1/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.